Oral Ketorolac PRN Dosing
For oral ketorolac (Toradol) used as-needed, the appropriate dose is 10 mg every 4-6 hours as needed, not to exceed 40 mg per day, and only as continuation therapy following initial IV/IM dosing—oral ketorolac should never be used as initial monotherapy. 1
Critical Prescribing Requirements
The FDA label is unequivocal about oral ketorolac use 1:
- Oral formulation is NOT approved as initial therapy—it must follow IV or IM dosing
- Total duration (IV/IM + oral combined) cannot exceed 5 days in adults
- Maximum daily oral dose: 40 mg/day regardless of age or weight
Specific Dosing by Patient Population
Standard Adult Patients (Age 17-64 years)
- Initial oral dose: 20 mg once (following IV/IM therapy)
- Subsequent PRN dosing: 10 mg every 4-6 hours as needed
- Daily maximum: 40 mg 1
High-Risk Patients (Age ≥65, weight <50 kg, or renal impairment)
- Initial oral dose: 10 mg once (following IV/IM therapy)
- Subsequent PRN dosing: 10 mg every 4-6 hours as needed
- Daily maximum: 40 mg 1
The dosing interval of 4-6 hours must not be shortened 1
Clinical Context from Guidelines
While the FDA label provides definitive dosing, clinical guidelines offer context. For acute pain management, ketorolac 60 mg IM was historically referenced 2, but this reflects older IM dosing practices. More recent cancer pain guidelines mention ketorolac 15-30 mg IV every 6 hours for maximum 5 days 3, emphasizing short-term use only.
Important caveat: The guideline evidence provided focuses primarily on IM/IV dosing for acute migraine 2 and cancer pain 3. These do not address oral PRN dosing specifically, making the FDA drug label 1 the definitive source for oral administration.
Safety Considerations
Absolute Contraindications
- NSAID-induced asthma
- Pregnancy (especially ≥30 weeks gestation) 1
- Cerebrovascular hemorrhage
- Active peptic ulcer disease or GI bleeding 3
High-Risk Populations Requiring Extreme Caution
- Age ≥60 years: Increased risk of renal, GI, and cardiac toxicity 3
- Cardiovascular disease: NSAIDs may worsen hypertension and increase bleeding risk with anticoagulants 3
- Renal impairment: Dose reduction mandatory; monitor creatinine 3
- Concurrent diuretics: Ketorolac reduces natriuretic effects 1
- Concurrent SSRIs or anticoagulants: Markedly increased bleeding risk 1
Common Pitfalls to Avoid
- Never prescribe oral ketorolac as first-line therapy—this violates FDA labeling 1
- Never exceed 5 days total duration (IV/IM + oral combined)—serious toxicity risk increases dramatically 1
- Never use in patients on lithium, methotrexate, or probenecid—dangerous drug interactions 1
- Never assume "PRN" means unlimited use—the 40 mg daily maximum and 5-day total duration are absolute limits 1
Monitoring Requirements
For patients receiving ketorolac (even short-term):
- Baseline and repeat (every 3 months if prolonged): BP, BUN, creatinine, liver function tests, CBC, fecal occult blood 3
- Discontinue immediately if: creatinine doubles, liver enzymes exceed 3x upper limit of normal, hypertension develops/worsens, or GI bleeding occurs 3
Evidence Quality Note
Recent systematic reviews 4, 5 suggest lower ketorolac doses (10-20 mg) may be as effective as higher doses (≥30 mg) with potentially fewer adverse effects, though this evidence is primarily for parenteral administration. The FDA-approved oral dosing of 10 mg PRN remains the standard 1, and any deviation from labeled dosing should be considered off-label practice.